|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Found 32 studies with search of: | Efavirenz / Emtricitabina / Tenofovir DF OR Atripla[TREATMENT] AND HIV [CONDITION] |
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Active, not recruiting |
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
|
||||
| 2 | Active, not recruiting |
Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 (QUAD) Versus Atripla(R) in HIV Infected, Antiretroviral Treatment-Naive Adults
|
||||
| 3 | Completed |
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
|
||||
| 4 | Withdrawn |
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
|
||||
| 5 | Active, not recruiting |
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
|
||||
| 6 | Completed |
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
|
||||
| 7 | Unknown † |
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
|
||||
| 8 | Active, not recruiting |
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
|
||||
| 9 | Recruiting |
Tissue Drug Levels of HIV Medications
|
||||
| 10 | Recruiting |
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
|
||||
| 11 | Completed |
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
|
||||
| 12 | Not yet recruiting |
Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection
|
||||
| 13 | Not yet recruiting |
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
|
||||
| 14 | Recruiting |
Atripla to Raltegravir Switch Study
|
||||
| 15 | Recruiting |
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
|
||||
| 16 | Active, not recruiting |
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
|
||||
| 17 | Unknown † |
Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens
|
||||
| 18 |
Completed
Has Results |
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
|
||||
| 19 | Withdrawn |
Raltegravir Activity In Lymphoid Tissues
|
||||
| 20 | Recruiting |
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
|
|
Previous Page | Studies Shown (1-20) | Next Page (21-32) |
|